Showing 1831-1840 of 3137 results for "".
The Price of a Penalty: Unraveling CMS's Latest Moves
https://practicaldermatology.com/topics/practice-management/the-price-of-a-penalty-unraveling-cmss-latest-moves/21435/State Legislation of EHRs: A Sweeping Precedent?
https://practicaldermatology.com/topics/practice-management/state-ehr-legislation-a-new-precedent/21483/A new law in Massachusetts requires all licensed physicians to be using an EHR by 2015.Analyzing the New Consensus Statement on Immunotherapy for Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-the-new-consensus-statement-on-immunotherapy-for-melanoma/21506/In-Review: Two New Melanoma Agents Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/in-review-two-new-melanoma-agents-approved/21534/Utilizing genetic abnormalities, new therapies are carving out new possibilities for melanoma treatment.Financial Benchmarking Update for Dermatology Practices
https://practicaldermatology.com/topics/practice-management/financial-benchmarking-update-for-dermatology-practices/21621/Successful practices use benchmarking to compare their performance to others, assess their own performance over time, and plan for the long term.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21848/Dermatology Q&A: Treating Melasma and Photoaging Without Hydroquinone
https://practicaldermatology.com/topics/general-topics/dermatology-qa-treating-melasma-and-photoaging-without-hydroquinone/21867/A recently unveiled skin brightening cream may signal a new direction in the treatment and prevention of pigmentation disorders.Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuBiologics and Beyond
https://practicaldermatology.com/topics/psoriasis/biologics-and-beyond/23554/A look at off-label use of biologics and JAK inhibitors.